Rasagiline mesylate (RSM) is a hydrophilic drug with poor oral bioavailability (36%)
because of hepatic first-pass metabolism. The present study focuses on delivering RSM …

The underlying causes of Parkinson's disease are complex, and besides recent advances in
elucidating relevant disease mechanisms, no disease-modifying treatments are currently …

Assessing imaging biomarker in the prodromal and early phases of Parkinson's disease
(PD) is of great importance to ensure an early and safe diagnosis. In the last decades …

Abstract Asymptomatic Leucine-Rich Repeat Kinase 2 Gene (LRRK2) carriers are at risk for
developing Parkinson's disease (PD). We studied presymptomatic substantia nigra pars …

Degeneration in the substantia nigra (SN) pars compacta (SNc) underlies motor symptoms
in Parkinson's disease (PD). Currently, there are no neuroimaging biomarkers that are …

The findings help improve the imaging-based diagnosis of PSP and CBD, allow more
targeted prognostic estimates for patients accounting for phenotype or disease, and will aid …

Parkinson's disease (PD) is an age‐related progressive neurodegenerative disorder
characterized by both motor and non‐motor symptoms resulting from the death of …

Background Parkinson's disease (PD) demonstrates neurodegenerative changes in the
substantia nigra pars compacta (SNc) using neuromelanin-sensitive (NM)-MRI. As SNc …

Accurate and timely diagnosis of atypical parkinsonian syndromes (APS) remains a
challenge. Especially early in the disease course, the clinical manifestations of the APS …

There has been a great development in imaging methods and their use for early diagnosis
of neurodegenerative disorders. The aim is to discover more sensitive biomarkers that would …